As a potential investor in psychedelics, you may be wondering how firms will generate meaningful revenues from this industry given that the pharmaceutical and biotech industries are investment-heavy. Well, the answer to this question seems to be that psychedelics companies that operate treatment clinics stand a higher chance of having a revenue edge over those that don’t have clinics.
Clinics are the logical way to go for psychedelic companies since, as anyone who has ever tried psychedelics will tell you, the psychedelic experience is a profound one that takes an individual on a journey into their own selves so that they get insights into what may be holding them back, or even uncover parts of themselves that had remained hidden from their consciousness.
Such a journey is best undertaken under the supervision of a trained psychedelic therapist operating in a controlled clinical setting. Psychedelic clinics address those two issues of availing trained professionals as well as an appropriate clinical setting where one can be safe to go where the psychedelics lead them.
Many such clinics are already opening their doors to patients within and outside the U.S. An example is The Center for Medicinal Mindfulness based in Boulder, Colorado.
As more and more clinics open up across the country, they are getting better organized, and so is their role in conducting psychedelic research getting more pronounced. Invariably, the mushrooming of these clinics is raising questions about what they can or can’t do, how they can safely offer the psychedelic treatments in order to manage various conditions, such as PTSD and substance abuse, as well as how the personnel serving in those clinics can be certified.
MAPS, or Multidisciplinary Association for Psychedelic Studies, is a nonprofit organization which is playing a huge role in getting answers to the questions above, and many others. During a virtual summit that recently attracted 1,400 attendees from more than 20 countries across the world, MAPS revealed that they are glad that for-profit entities are getting involved in the psychedelics industry since the resources that they command can enable the sector to move faster towards availing these needed treatments on a massive scale.
Rick Doblin, the MAPS executive director, spoke during that virtual event. He said that they expect thousands of psychedelic clinics to be operational by 2030, and that creates a huge demand for trained and certified psychedelic-assisted psychotherapy professionals.
Doblin explains that MAPS is working towards addressing the needs of those approximately 6,000 clinics which will be open by the end of this decade. In fact, MAPS is already training trainers so that it will be possible to ramp up the number of certified personnel to run the clinics.
The certification program that MAPS runs currently lasts six months, and so far, they are only accepting practicing therapists to enroll for this program. Later, the training will be open to anyone interested. As these trained people are absorbed into the clinics, patients can be sure that they will go through the same treatment process regardless of the clinic that they visit, as long as that clinic was licensed to offer psychedelic treatment.
Analysts say such structured and responsible growth could give sector players like Numinous and Pure Extracts Corp. added impetus to ramp up their R&D since the industry appears poised to take off in a big way.
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.